Key Takeaways
- Record quarter, driven by pricing and utilization: Revenue hit ₹533 Cr (up 84% YoY) as plant utilization reached 94% and realizations surged, pushing EBITDA margins to 37%.
- Two new plants commissioned on time and budget: India's first glycerol-based epichlorohydrin plant and its largest CPVC resin plant are now online, with volume ramp-ups expected to begin in Q3.
- Management is confident in FY23 guidance, with an upside bias: The 50% revenue growth target is reaffirmed, and while official margin guidance remains 28% ±2%, a repeat of Q1's pricing could push that to 31-32%.
- The long-term story is shifting to derivatives: Nearly 60% of the ₹5,000 Cr FY27 revenue target is expected to come from value-added derivatives, with all future capex focused downstream of chlorine and caustic soda.
- What to watch next quarter: Customer approvals for CPVC resin, the pace of ECH export order conversion, and whether caustic soda prices hold at elevated levels as European energy costs remain high.
New Plant Commissioning & Ramp-Up
- ECH plant online: India's first epichlorohydrin plant, using the glycerol process, was commissioned on June 1, 2022, within its timeline and capex budget. Trial orders have been sent to customers in India, Europe, and the US.
- CPVC resin plant online: India's largest CPVC resin plant (30,000 tonnes per annum) was commissioned on July 18, 2022. Trial orders are underway with all major pipe and fitting manufacturers, with initial trials expected to finish by month-end.
- Volume ramp-up timeline: Both ECH and CPVC are expected to see actual sales volumes begin in Q3 FY23, following a 45-75 day customer approval and trial cycle. CPVC is expected to reach optimum capacity by end of Q4 FY23 or early Q1 FY24.
- CPVC capacity ceiling: The CPVC plant has a maximum initial operating rate of 75%, not 100%, due to the nature of the process technology.
- Combined revenue potential: At optimum capacity and current raw material prices, ECH and CPVC together can generate ₹1,200-1,300 Cr in annual revenue.
- Market positioning is additive, not disruptive: Management stated it will not replace existing CPVC suppliers; it will supply additional resin to a domestic market growing at double digits, where no new global capacity is being added.
Maulik J Patel: "If you do an analysis well of the CPVC market in India there is no replacement required. Indian market is continuously increasing double digit growth and the worldwide there is no capacity expansion of the CPVC resin so we are not going to replace anyone. The people who are growing they require additional resin we will supply them."
Caustic Soda: Pricing & Expansion
- Price resilience explained: Caustic soda prices saw only a slight correction, unlike other commodities, because European and US markets are gas-based economies with high production costs, and Chinese lockdowns did not impact those regions. High energy costs worldwide are expected to keep prices elevated.
- Expansion on track: The caustic soda capacity expansion from 294,000 to 400,000 tonnes per annum is likely to be commissioned by the end of Q2 FY23. Unlike ECH and CPVC, this new capacity does not need a ramp-up period due to existing customer approvals and operational experience.
- Demand absorption thesis: Management believes domestic caustic soda demand, driven by GDP growth, infrastructure spending, PLI schemes, and the agrochemical and pharmaceutical sectors, will absorb all new capacity over time.
- Utilization forecast: Optimum capacity utilization for caustic soda is forecast at about 90% on a pro-rata basis, even on the incremental capacity.
Maulik J Patel: "I think most the answer I will give you in a different way because yes you are right there is a slight correction in the caustic soda price but if you see the other commodities and other products which are reduced that much price reduction is not there in the caustic soda... the caustic soda price the correction which will not happen as much as it is in the other products."
Margin & Profitability Dynamics
- Q1 margin surge: EBITDA margin expanded 333 bps QoQ to 37%, driven by higher realizations and 94% plant utilization. PAT tripled to ₹108 Cr, with PAT margins at 20%.
- Full-year margin guidance is deliberately conservative: Official guidance remains 28% ±2%, but management acknowledged that if Q1's elevated pricing environment persists, margins above 30% are achievable. The conservative stance reflects an expectation that commodity prices will normalize.
- New products will dilute margin rate, not absolute profit: ECH and CPVC have lower EBITDA margins but higher asset turnover ratios, meaning absolute EBITDA will increase even as the blended margin rate compresses.
- Return ratios transformed: ROCE improved to 33% from 19% YoY, and ROE to 48% from 22% YoY. Debt-to-EBITDA improved to 1.6x despite increased debt for capex.
Milind Kotecha: "When we have given a guidance of 28% plus or minus to EBITDA margin that is for a longer period of time. It has nothing related to the current commissioning of the ECH and CPVC so in this quarter also the prices that were in Q1 if that kind of situation maintains we can make the margins of 31% to 32% but we know the current prices are elevated and it will go down to some level and that is why on a conservative side we are saying 28% plus or minus 2%."
The ₹5,000 Crore Vision & Capital Allocation
- FY27 roadmap: Management is targeting ₹5,000 Cr in revenue by FY27 with strong ROCE. Nearly 60% of that revenue is expected to come from value-added derivatives and specialty chemicals, not commodity chlor-alkali products.
- Post-expansion strategy: After the current chlor-alkali expansion, all future capex will focus on downstream value-added products derived from chlorine, hydrogen, or caustic soda. The strategy is to be an integrated player focused on import-substitute molecules for the domestic market.
- India demand underpins the vision: Management expects Indian chemical consumption to grow at least in single digits even in a global recession scenario, providing a stable demand base. More projects will be announced each year as CPVC stabilizes.
- Future ECH/CPVC expansion is probable but not committed: Both products have a high chance of future expansion, but decisions will depend on returns generated and whether better opportunities exist in other molecules.
- Balance sheet strengthening: Long-term debt is expected to reduce to around ₹550 Cr by March 31, 2023. Full-operation depreciation will be around ₹120 Cr annually, and maintenance capex is expected at ~2% of gross block.
Maulik J Patel: "Definitely more than double digit growth it will not come in the future due to the global recession but at least single digit will grow so we are not in the place where the market and the demand will diminish like or we are not growing."
Cost & Input Environment
- Power cost: Captive power generation cost was around ₹9.5 per unit in Q1. A slight cooling effect from lower coal prices is expected in Q2 and Q3, but management said it is too early to quantify the per-unit cost for the current quarter.
- Glycerin availability improving: Glycerin prices are declining as Indonesia lifted its palm oil export ban and increased biodiesel blending to 30-35%, which produces glycerin as a byproduct. This is a positive sign for ECH raw material availability.
- Chlorine integration benefit: Chlorine realization was negative at around ₹4.5 per kg, but the integrated model allows the company to capture value in derivative plants when chlorine is negative, and in the caustic soda plant when it is positive.
- Inventory build-up is strategic: The increase in inventory on the balance sheet is due to stocking of raw materials (PVC and glycerin) for the newly commissioned ECH and CPVC plants, with a policy of maintaining at least two months of inventory.
Macro Uncertainty & Risk
- Uncertainty expected to persist: Management cited the Russia-Ukraine conflict, elevated energy and gas prices, crude oil volatility, and China lockdowns as creating an unpredictable environment that is likely to continue at least through Q2 and Q3.
- Guidance review is data-dependent: Management declined to revise full-year guidance based on one exceptional quarter, stating it will assess Q2 and possibly Q3 performance before revisiting targets on the next call.
- Export exposure is currently low but growing: Exports were only 5-7% of revenue in Q1, but this percentage is expected to increase from Q3 onwards as ECH exports to different continents begin.
Maulik J Patel: "As of now I do not think so but I think definitely the world is looking after the what action is Russia is doing with Ukraine because of that the current energy cost and the current gas prices and current crude oil prices and the China lockdown such kind of scenario is very difficult to predict for a longer period of time so yes there is uncertainty in this kind of reasons it is going to be there and it will continue I think probably at least in Q2 and Q3 at least."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 50% YoY growth for FY23, driven by ECH, CPVC, and caustic soda expansion volumes | FY23 |
| EBITDA margin | 28% ±2% for the full year; 31-32% achievable if Q1 pricing sustains | FY23 |
| Caustic soda expansion commissioning | Capacity increase from 294,000 to 400,000 tonnes per annum | End of Q2 FY23 |
| CPVC volume ramp-up | Actual sales to begin post customer approval process (~3 months from commissioning) | Q3 FY23 onwards |
| ECH volume ramp-up | Actual sales to begin after trial orders convert to new orders | Q3 FY23 onwards |
| CPVC optimum utilization | Reach maximum initial capacity of 75% | End of Q4 FY23 or early Q1 FY24 |
| ECH optimum utilization | Reach full capacity | Q4 FY23 |
| Wind-solar hybrid plant commissioning | 18.34 MW power plant via JV | Q3 FY23 |
| Long-term debt reduction | Reduce to ~₹550 Cr | By March 31, 2023 |
| Long-term revenue target | ₹5,000 Cr revenue with ~60% from derivatives and specialties | FY27 |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹533 cr, +84% YoY |
| EBITDA | ₹187 cr, doubled YoY |
| EBITDA margin | 37%, vs 32% in Q1 FY22, +333 bps YoY |
| PAT | ₹108 cr, grew 3x YoY |
| PAT margin | 20% |
| Overall plant utilization | 94%, vs 88% in FY22 |
| Caustic soda capacity utilization | 104% |
| Caustic potash capacity utilization | 130% |
| Chlorotoluene capacity utilization | 105% |
| ROCE | 33%, vs 19% in Q1 FY22 |
| ROE | 48%, vs 22% in Q1 FY22 |
| Debt to EBITDA | 1.6x, vs 2.x in Q1 FY22 |
| Long-term debt | ₹690 cr as of Jun 30, 2022; expected to reduce to ₹550 cr by Mar 31, 2023 |
| Captive power generation cost | ₹9.5 per unit |
| ECU for caustic | ₹50,000, slightly higher than Q4 FY22 level of ~₹49,000 |
| Negative chlorine realization | ₹4.5 per kg |
| Exports as percentage of total revenue | 5% to 7% |
| Capex spent in Q1 FY23 | ₹57 cr, against full-year budget of ₹180 cr |
| Full-year FY23 revenue growth guidance | 50% |
| Full-year FY23 EBITDA margin guidance | 28% plus or minus 2% |
| ECH current price | ₹215 to ₹220 per kg, down from peak of ₹225–₹250 |
| CPVC plant maximum initial capacity utilization | 75% |
| ECH + CPVC combined annual revenue at optimum utilization | ₹1,200 cr to ₹1,300 cr |
| Interest rate | 7.5% range from Q1 FY23 onwards, up from sub-7% till FY22 |
| Full-operation annual depreciation | ~₹120 cr after commissioning all plants |